Table 1.
Patient and transplant characteristics (n = 208)
| Patient age, y, median (range) | 53 (19-77) |
| Sex, male (%) | 129 (62) |
| Diagnosis, n (%) | |
| Myeloid diseases | |
| AML | 122 (59) |
| MDS or MPN | 32 (15) |
| Lymphoid diseases/myeloma | 54 (26) |
| Disease status at HSCT, n (%) | 57 (27) |
| CR1 | |
| CR > 1 | 28 (14) |
| Active disease | 123 (59) |
| R-DRI at HSCT, n (%) | |
| Not applicable | 10 (5) |
| Low or intermediate | 82 (39) |
| High | 93 (45) |
| Very high | 23 (11) |
| HCT-CI score, median (range) | 2 (0-8) |
| Type of donor, n (%) | |
| MRD | 39 (19) |
| UD | 63 (30) |
| MMRD | 99 (48) |
| CBU | 7 (3) |
| Stem cell source, n (%) | |
| PB | 181 (87) |
| BM | 20 (10) |
| CBU | 7 (3) |
| Conditioning regimen, n (%) | |
| MAC | 169 (81) |
| RTC | 39 (19) |
| CMV serostatus (H/D), n (%) | |
| Pos/pos | 115 (55) |
| Pos/neg | 66 (32) |
| Neg/pos | 7 (3) |
| Neg/neg | 20 (10) |
| GVHD prophylaxis, n (%) | |
| In vivo T-cell depletion | |
| PT-Cy–based | 101 (49) |
| ATG-based | 84 (40) |
| None | 23 (11) |
| Immunesuppression | |
| Sirolimus-based | 161 (78) |
| CsA-based | 47 (22) |
AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; CBU, cord blood unit; CR, complete remission; CsA, cyclosporine A; HCT-CI, hematopoietic cell transplant–comorbidity index; H/D, host/donor; HL, Hodgkin lymphoma; MAC, myeloablative conditioning22,23; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; MRD, matched-related donor; MMRD, mismatched related donor; neg, negative; PB, peripheral blood; pos, positive; R-DRI, refined-disease risk index; RTC, reduced-toxicity conditioning24,25; UD, unrelated donor.